PCM
IMDZ

Portolan Capital Management’s Immune Design Corp. IMDZ Stock Holding History

Portolan Capital Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-726,086
Closed -$2.5M – 113
2018
Q3 		$2.5M Buy
726,086
+281,211
+63% +$1.06M 0.25% 76
2018
Q2 		$2.02M Buy
+444,875
New +$1.77M 0.21% 81

Other funds holding IMDZ

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Portolan Capital Management's IMDZ Position: Q4 2018 in Review

Portolan Capital Management sold out of Immune Design Corp. (IMDZ) in Q4 2018, closing a stake of 726,086 shares — an estimated $2.5M sold.

Portolan Capital Management first reported a position in IMDZ in Q2 2018 and held it in 2 quarters. The position peaked at $2.5M in Q3 2018. 64 funds tracked by Wall St. Rank hold IMDZ as of Q4 2018.

  • Portolan Capital Management reported no remaining Immune Design Corp. position as of Q4 2018 after selling out during the quarter.
  • Portolan Capital Management sold 726,086 Immune Design Corp. shares in Q4 2018, an estimated $2.5M.
  • Portolan Capital Management first reported a position in Immune Design Corp. in Q2 2018 and held it in 2 quarters.
  • Portolan Capital Management's Immune Design Corp. position peaked at $2.5M in Q3 2018.
  • 64 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2018.

Based on Portolan Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.